An upcoming study exploring new oral antivenoms could significantly change how snakebites are treated in rural Ghana, particularly in high-burden communities in the Upper West Region. Snakebite envenoming remains a life-threatening but neglected public health problem, with antivenoms currently the only specific treatment available. Conventional intravenous (IV) antivenoms are difficult to deploy in remote settings, as they require cold-chain storage, trained staff, hospital-based administration, and carry some risk of severe allergic reactions. Stockouts and delayed access continue to cost lives and leave many survivors with permanent disabilities. The study, which is scheduled to take place in Ghana and Brazil, will evaluate the potential of oral antivenoms, small-molecule drugs designed to target key venom components that are conserved across multiple snake species.